Midas Care Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Midas Care Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Midas Care Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.1M Trade | TransData Nexus

Midas Care Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $1.1M Total Trade · DGFT Verified

Midas Care Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 3 products in 1 therapeutic categories. Based on 24 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Salmeterol ($623.8K), Fluticasone ($350.0K), Ipratropium ($150.0K).

Midas Care Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Midas Care Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Midas Care Pharmaceuticals Private Limited? — Company Overview & Market Position

Midas Care Pharmaceuticals Private Limited, established on May 16, 1986, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24239MH1986PTC039852. Its authorized share capital is ₹2,000,000, with a paid-up capital of ₹609,000. Midas Care Pharmaceuticals specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates across various therapeutic categories, with a notable presence in the respiratory segment. As of the latest available data, Midas Care Pharmaceuticals employs between 1,001 and 5,000 individuals. The company's official website is www.midas-care.com.

What Does Midas Care Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Salmeterol$623.8K 2Fluticasone$350.0K

Product Portfolio — Top 3 by Export Value

Midas Care Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Salmeterol	Respiratory	$623.8K	14	0.6%	9
2	Fluticasone	Respiratory	$350.0K	7	0.2%	7
3	Ipratropium	Respiratory	$150.0K	3	0.3%	12

Midas Care Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $1.1M. The top category is Respiratory (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Midas Care Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Midas Care Pharmaceuticals operates multiple manufacturing facilities across India, including locations in Aurangabad, Maharashtra; Una, Himachal Pradesh; and Amingaon, Kamrup, Assam. These facilities are equipped to produce a diverse range of pharmaceutical products, adhering to stringent quality standards. The company's manufacturing capabilities are supported by advanced technology and comprehensive research and development (R&D) services, enabling the production of both generic and specialized formulations.

3Key Leadership

The leadership team at Midas Care Pharmaceuticals includes Managing Director Sangithaa Gupta Brijbandhu, who has been with the company since its inception in 1986. Other key directors are Shivangi Gupta, appointed on October 21, 2005, and Nandan Brijbandhu Gupta, who joined the board on March 1, 2011. The company's leadership is committed to driving growth and innovation in the pharmaceutical sector, focusing on delivering high-quality products to a global market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Midas Care Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Midas Care Pharmaceuticals has made significant strides in expanding its presence in regulated markets, particularly in the United States. The company has obtained approvals for several over-the-counter (OTC) medications, including the Relispray Natural Pain Relief and Relispray Antifungal Powder, with FDA filings dated November 5, 2025, and December 20, 2024, respectively. (fda.report) These approvals indicate the company's commitment to meeting international regulatory standards and expanding its footprint in the U.S. market. While specific details regarding approvals in the European Union, United Kingdom, Australia, and Japan are not readily available, Midas Care Pharmaceuticals' focus on quality and compliance suggests potential for future market access in these regions.

2Emerging Markets

Midas Care Pharmaceuticals has demonstrated a proactive approach to penetrating emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's commitment to quality is evident through its adherence to international manufacturing standards, which is crucial for gaining market access in these regions. While specific details regarding WHO prequalification are not available, the company's focus on quality and compliance positions it favorably for future expansion into these markets.

Geographic Strategy

Midas Care Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Midas Care Pharmaceuticals has made notable progress in obtaining FDA approvals for its products. The company's FDA filings include OTC medications such as the Relispray Natural Pain Relief and Relispray Antifungal Powder, with approval dates of November 5, 2025, and December 20, 2024, respectively. (fda.report) These approvals reflect the company's commitment to meeting stringent regulatory standards and expanding its presence in the U.S. market. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not readily available, the existing approvals indicate a positive regulatory standing.

2WHO & EU GMP

Specific information regarding Midas Care Pharmaceuticals' WHO prequalification and EU Good Manufacturing Practice (GMP) certifications is not readily available. However, the company's adherence to international manufacturing standards and its focus on quality suggest a commitment to obtaining such certifications. These certifications are crucial for market access in various regions and reflect the company's dedication to maintaining high manufacturing standards.

CDSCO & Indian Regulatory

Midas Care Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Midas Care Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not readily available, the company's focus on the respiratory therapeutic category positions it among competitors in this segment. The company's export data indicates a concentration in respiratory products, suggesting a strategic emphasis on this area. Additionally, Midas Care Pharmaceuticals' expansion into regulated markets, such as the United States, and its presence in emerging markets demonstrate a strategic direction aimed at diversification and risk mitigation.

2Key Differentiators

Midas Care Pharmaceuticals distinguishes itself through its comprehensive approach to pharmaceutical manufacturing, encompassing R&D, production, and distribution. The company's ability to produce a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, showcases its manufacturing versatility. Its focus on the respiratory therapeutic category, with products like Salmeterol, Fluticasone, and Ipratropium, aligns with global health trends and demand. The company's expansion into regulated markets, such as the United States, and its presence in emerging markets reflect a strategic direction aimed at diversification and risk mitigation.

Strategic Position

Buyer Due Diligence Brief — Evaluating Midas Care Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Midas Care Pharmaceuticals has established itself as a reliable supplier in the pharmaceutical industry, with a total export value of $1.1 million USD across 24 shipments. The company's export portfolio is concentrated in the respiratory therapeutic category, with top products like Salmeterol, Fluticasone, and Ipratropium accounting for a significant portion of its export value. This concentration indicates a focused approach to product offerings. The company's adherence to international manufacturing standards and its proactive approach to obtaining regulatory approvals, such as FDA filings for products like the Relispray series, reflect its commitment to quality and reliability. (fda.report)

2Certifications to Verify

Importers should verify the following certifications when considering Midas Care Pharmaceuticals as a supplier:

FDA Registration: Confirm the company's FDA facility registrations and approved product listings to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards, which is crucial for market access in various regions.

Frequently Asked Questions — Midas Care Pharmaceuticals Private Limited

How many pharmaceutical products does Midas Care Pharmaceuticals Private Limited export from India?

Midas Care Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Salmeterol ($623.8K), Fluticasone ($350.0K), Ipratropium ($150.0K). Total export value is $1.1M.

What is Midas Care Pharmaceuticals Private Limited's total pharmaceutical export value?

Midas Care Pharmaceuticals Private Limited's total pharmaceutical export value is $1.1M, based on 24 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Midas Care Pharmaceuticals Private Limited cover?

Midas Care Pharmaceuticals Private Limited exports across 1 therapeutic categories. The largest are Respiratory (100.0%, 3 products).

Get Full Midas Care Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.